Nimesulide for acute and chronic pain management Review article
Article Sidebar
Published:
Dec 31, 2013
Keywords:
NSAIDS – mechanism of action, classification, adverse effects, nimesulide, acute pain, chronic pain
Main Article Content
Abstract
This paper is dedicated to the role of COX2 selective, non-steroidal anti-inflammatory drug nimesulide in acute and chronic pain management. Its mode of action, as well as advantages and disadvantages are presented. Special interest is paid to its role in postoperative, trauma-related and chronic pain management in gynecology, neurology, orthopedic surgery, rheumatic disorders and family physician practice.
Article Details
How to Cite
Wordliczek, J., Woroń , J., Woroń , J., Dębski , R., Sienkiewicz-Jarosz , H., Romanowski, L., Wiland, P., Lukas, W., & Malec-Milewska, M. (2013). Nimesulide for acute and chronic pain management. Medycyna Faktow (J EBM), 6(4(21), 50-61. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2396
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Acute pain Management: Scientific Evidence. Cousins M.J. (red.). A.N.Z.C.A., Sidney, 2005.
2. Bendtsen L., Evers S., Linde M. et al.: EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur. J. Neurol. 2010; 7(11): 1318-25.
3. Bevilacqua M., Devogelaer J.P., Righini V. et al.: Effects of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int. J. Clin. Pract. 2004; 144(suppl.): 13-19.
4. Bianchi M., Broggini M.: A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63(suppl. 1): 37-46.
5. Binning A.: Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin. J. Pain. 2007; 23: 565-570.
6. Bourgeois P., Dreiser R.L., Lequesne M.G. et al.: Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur. J. Rheumatol. Inflamm. 1994; 14(2): 39-50.
7. Charakterystyka Produktu Leczniczego – Aulin, 2008.
8. Charlot M., Grove E.L. et al.: Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690.
9. da Costa Araújo F.A. et al.: Comparative analysis of preemptive analgesic effect of tramadol chlorhydrate and nimesulide following third molar surgery. Journal of Cranio-Maxillo-Facial Surgery 2012; 40: 346-349.
10. De Menezes S.A.F., Cury P.R.: Efficacy of nimesulide versus meloxicam in the control of pain, swelling and trismus following extraction of impacted lower third molar. Int. J. Oral Maxillofac. Surg. 2010; 39: 580-584.
11. Dębski R., Niemiec T., Mazurek M. et al.: Porównanie skuteczności i tolerancji 80 mg drotaweryny i 400 mg ibuprofenu u pacjentek z pierwotnym bolesnym miesiączkowaniem – badanie DOROTA. Gin. Pol. 2007; 78(12): 933-938.
12. Dreiser R.L., Riebenfeld R.D.: Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo. Drugs 1993; 46(suppl. 1): 191-5.
13. Evers S., Afra J., Frese A.: European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur. J. Neurol. 2009; 16(9): 968-81.
14. Gomez-Batiste X., Madrid F., Moreno F. et al.: Breakthrough Cancer Pain: Prevalence and Characteristics in Patients in Catalonia, Spain. Jour. of Pain and Symp. Manag. 2002; 1(24): 45-52.
15. Gulmez S.E., Larrey D. et al.: Transplantation for Acut Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen). Drug Saf. 2013; 36: 135-144.
16. Hochberg M.C., Altman R.D., April K.T. et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacological and pharmacologic therapies in osteoarthritis of the hand, hip and knee. Arthritis Care & Research 2012; 64: 465-474.
17. Huskisson E.C., Macciocchi A., Rahlfs V.W. et al.: Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr. Ther. Res. 1999; 60: 253-265.
18. Jenoure P., Gorshewsky O., Ryf C. et al.: Randomized, double-blind, multicenter study of nimesulide vs. diclofenac in adults with acute sport injuries. J. Clin. Res. 1998; 1: 343-356.
19. Johnson N.: Management of dysmenorrhoea. Reviews in Gynaecological and Perinatal Practice 2006; 6: 57-62.
20. Khan M.A. et al.: A phase III trial evaluating the efficacy and tolerability of nimesulide 1% spray in patients with soft-tissue injuries. Int. J. Crit. Illn. Inj. Sci. 2013; 3: 18-24.
21. Koda-Kimble M.A., Young L.Y., Alldredge B.K. et al.: Applied Therapeutics. Wolters Kluwer, Philadelphia 2009.
22. Konstantinovic L.M., Kanjuh Z.M., Milovanovic A.N. et al.: Acute low back pain with radiculopathy: a double-blind, randomized, placebocontrolled study. Photomed. Laser Surg. 2010; 28(4): 553-60.
23. Kostka-Trąbka E., Woroń J.: Interakcje leków w praktyce klinicznej, Wydawnictwo Lekarskie PZWL, Warszawa 2011.
24. Kriegel W., Korff K.J., Ehrlich J.C. et al.: Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int. J. Clin. Pract. 2001; 55(8): 510-4.
25. Malec-Milewska M., Wordliczek J.: Ostre zespoły bólowe – właściwy wybór leku przeciwbólowego. Wordliczek J. (red.). Akademia Leczenia Bólu. Ogólnopolski Program Edukacyjny 2013.
26. Mayor S.: Risk of aspirin outweigh benefits in people without cardiovascular disease, shows analysis. BMJ 2012; 344: e241.
27. Międzybrodzki R.: Kierunki poszukiwań i zastosowanie niesteroidowych leków przeciwzapalnych. Postępy Hig. Med. Dośw. 2004; 58: 438-448.
28. Mukherjee D., Nissen S.E., Topol E.J.: Risc of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
29. NICE clinical guideline 88.
30. Nurmohamed M.T., van Halm V.O., Dijkmans B.A.C.: Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62: 1599-1609.
31. Omololu B., Alonge T.O., Oguniade S.O.: Double blind clinical trial comparing the safety and efficacy of nimesulide and diclofenac in osteoarthrosis of the hip and knee joints. WAJM 2005; 24(2): 128-133.
32. Pain 2005 – An Updated Review. IASP Press, 2005.
33. Pirhonen J., Pulkkinen M.: The effect of nimesulide and naproxen on the uterine and ovarian arterial blood flow velocity. A Doppler study. Acta Obstet. Gynecol. Scand. 1995; 74(7): 549-553.
34. Pohjolainen T., Jekunen A., Autio L. et al.: Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila. Pa 1976) 2000; 25(12): 1579-85.
35. Przeklasa-Muszyńska A., Dobrogowski J., Wordliczek J.: Koanalgetyki w leczeniu bólu przewlekłego. Terapia 2010; 11-12: 78-84.
36. Pulkkinen MO.: Nimesulide in dysmenorrhoea. Drugs 1993; 46(suppl. 1): 129-33.
37. Pulkkinen M.O., Monti T., Macciocchi A.: Analysis of uterine contractility after administration of the non-steroidal anti-inflammatory drug nimesulide. Acta Obstet. Gynecol. Scand. 1992; 71(3): 181-185.
38. Pulkkinen M.O.: Is there a rationale for the use of Nimesulide in the treatment of Dysmenorrhea? Drugs of Today 2001; 37(suppl. B): 31-38.
39. Rainsford K.D.: Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr. Med. Res. Opin. 2006; 22: 1161-1170.
40. Raju N.C., Eikelboom J.W.: The aspirin controversy in primary prevention. Curr. Opin. Cardiol. 2012; 27: 499-507.
41. Romella G., Costagli V., Vetere M. et al.: Comparision of nimesulide and diclofenac in the prevention and treatment of pain and inflammatory postoperative complications of general surgery. Drugs 1993; 46(suppl. 1): 159-161.
42. Ruoff G., Lema M.: Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J. Pain Symptom. Manage. 2003; 25(suppl. 2): 21-31.
43. Sarzi-Puttini P., Santandrea S., Booccassini L. et al.: The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin. Exp. Rheumatol. 2001; 19(suppl. 22): S17-20.
44. Shah A.A., Thjodleifsson B., Murray F.E. et al.: Selective hibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339-346.
45. Sudano I., Flammer A.J., Roas S. et al.: Nonsteroidal antiinflammatory drugs, acetaminophen and hypertension. Curr. Hypertens. Rep. 2012; 14: 304-309.
46. Sato K., Takahashi H., Toriyama M.: Depigmenting mechanism of NSAIDs on B16F1 melanoma cells. Arch. Dermatol. Res. 2011; 303(3): 171-80.
47. Stępień A.: Bóle głowy. Patofizjologia. Diagnostyka. Leczenie. Medical Tribune Polska, 2010.
48. Venegoni M., Da Cas R., Menniti-Ippolito F. et al.: Następstwa europejskich działań ograniczających przepisywanie nimesulidu: badanie symulacyjne dotyczące zaburzeń czynności wątroby i krwawienia z przewodu pokarmowego przeprowadzone we Włoszech. Ann. Ist. Super Sanita. 2010; 2(46): 153-157.
49. Wielosz E.: Bezpieczeństwo stosowania inhibitorów cyklooksygenazy 2 w racjonalnej terapii bólu ostrego i przewlekłego. Evid. Based Med. 2013; 2(6) (reprint).
50. Wober W.: Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and meta-analysis of controlled studies with nimesulide. Rheumatology 1999; 38(suppl. 1): 33-38.
51. Wordliczek J., Filipczak-Bryniarska I. Wordliczek J. (red.). Akademia Leczenia Bólu. Ogólnopolski Program Edukacyjny 2013.
52. Woroń J.: Wybór niesteroidowego leku przeciwzapalnego w praktyce klinicznej. W: Akademia Leczenia Bólu. Ogólnopolski Program Edukacyjny. Wordliczek J. (red.). 2013.
53. Wordliczek J., Dobrogowski J.: Leczenie bólu. PZWL, 2012.
54. Zenz M., Strumpf M., Strumph-Willweber A.: Leczenie bólu. MedPharm Polska, Wrocław 2011.
2. Bendtsen L., Evers S., Linde M. et al.: EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur. J. Neurol. 2010; 7(11): 1318-25.
3. Bevilacqua M., Devogelaer J.P., Righini V. et al.: Effects of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int. J. Clin. Pract. 2004; 144(suppl.): 13-19.
4. Bianchi M., Broggini M.: A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63(suppl. 1): 37-46.
5. Binning A.: Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin. J. Pain. 2007; 23: 565-570.
6. Bourgeois P., Dreiser R.L., Lequesne M.G. et al.: Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur. J. Rheumatol. Inflamm. 1994; 14(2): 39-50.
7. Charakterystyka Produktu Leczniczego – Aulin, 2008.
8. Charlot M., Grove E.L. et al.: Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690.
9. da Costa Araújo F.A. et al.: Comparative analysis of preemptive analgesic effect of tramadol chlorhydrate and nimesulide following third molar surgery. Journal of Cranio-Maxillo-Facial Surgery 2012; 40: 346-349.
10. De Menezes S.A.F., Cury P.R.: Efficacy of nimesulide versus meloxicam in the control of pain, swelling and trismus following extraction of impacted lower third molar. Int. J. Oral Maxillofac. Surg. 2010; 39: 580-584.
11. Dębski R., Niemiec T., Mazurek M. et al.: Porównanie skuteczności i tolerancji 80 mg drotaweryny i 400 mg ibuprofenu u pacjentek z pierwotnym bolesnym miesiączkowaniem – badanie DOROTA. Gin. Pol. 2007; 78(12): 933-938.
12. Dreiser R.L., Riebenfeld R.D.: Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo. Drugs 1993; 46(suppl. 1): 191-5.
13. Evers S., Afra J., Frese A.: European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur. J. Neurol. 2009; 16(9): 968-81.
14. Gomez-Batiste X., Madrid F., Moreno F. et al.: Breakthrough Cancer Pain: Prevalence and Characteristics in Patients in Catalonia, Spain. Jour. of Pain and Symp. Manag. 2002; 1(24): 45-52.
15. Gulmez S.E., Larrey D. et al.: Transplantation for Acut Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen). Drug Saf. 2013; 36: 135-144.
16. Hochberg M.C., Altman R.D., April K.T. et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacological and pharmacologic therapies in osteoarthritis of the hand, hip and knee. Arthritis Care & Research 2012; 64: 465-474.
17. Huskisson E.C., Macciocchi A., Rahlfs V.W. et al.: Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr. Ther. Res. 1999; 60: 253-265.
18. Jenoure P., Gorshewsky O., Ryf C. et al.: Randomized, double-blind, multicenter study of nimesulide vs. diclofenac in adults with acute sport injuries. J. Clin. Res. 1998; 1: 343-356.
19. Johnson N.: Management of dysmenorrhoea. Reviews in Gynaecological and Perinatal Practice 2006; 6: 57-62.
20. Khan M.A. et al.: A phase III trial evaluating the efficacy and tolerability of nimesulide 1% spray in patients with soft-tissue injuries. Int. J. Crit. Illn. Inj. Sci. 2013; 3: 18-24.
21. Koda-Kimble M.A., Young L.Y., Alldredge B.K. et al.: Applied Therapeutics. Wolters Kluwer, Philadelphia 2009.
22. Konstantinovic L.M., Kanjuh Z.M., Milovanovic A.N. et al.: Acute low back pain with radiculopathy: a double-blind, randomized, placebocontrolled study. Photomed. Laser Surg. 2010; 28(4): 553-60.
23. Kostka-Trąbka E., Woroń J.: Interakcje leków w praktyce klinicznej, Wydawnictwo Lekarskie PZWL, Warszawa 2011.
24. Kriegel W., Korff K.J., Ehrlich J.C. et al.: Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int. J. Clin. Pract. 2001; 55(8): 510-4.
25. Malec-Milewska M., Wordliczek J.: Ostre zespoły bólowe – właściwy wybór leku przeciwbólowego. Wordliczek J. (red.). Akademia Leczenia Bólu. Ogólnopolski Program Edukacyjny 2013.
26. Mayor S.: Risk of aspirin outweigh benefits in people without cardiovascular disease, shows analysis. BMJ 2012; 344: e241.
27. Międzybrodzki R.: Kierunki poszukiwań i zastosowanie niesteroidowych leków przeciwzapalnych. Postępy Hig. Med. Dośw. 2004; 58: 438-448.
28. Mukherjee D., Nissen S.E., Topol E.J.: Risc of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
29. NICE clinical guideline 88.
30. Nurmohamed M.T., van Halm V.O., Dijkmans B.A.C.: Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62: 1599-1609.
31. Omololu B., Alonge T.O., Oguniade S.O.: Double blind clinical trial comparing the safety and efficacy of nimesulide and diclofenac in osteoarthrosis of the hip and knee joints. WAJM 2005; 24(2): 128-133.
32. Pain 2005 – An Updated Review. IASP Press, 2005.
33. Pirhonen J., Pulkkinen M.: The effect of nimesulide and naproxen on the uterine and ovarian arterial blood flow velocity. A Doppler study. Acta Obstet. Gynecol. Scand. 1995; 74(7): 549-553.
34. Pohjolainen T., Jekunen A., Autio L. et al.: Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila. Pa 1976) 2000; 25(12): 1579-85.
35. Przeklasa-Muszyńska A., Dobrogowski J., Wordliczek J.: Koanalgetyki w leczeniu bólu przewlekłego. Terapia 2010; 11-12: 78-84.
36. Pulkkinen MO.: Nimesulide in dysmenorrhoea. Drugs 1993; 46(suppl. 1): 129-33.
37. Pulkkinen M.O., Monti T., Macciocchi A.: Analysis of uterine contractility after administration of the non-steroidal anti-inflammatory drug nimesulide. Acta Obstet. Gynecol. Scand. 1992; 71(3): 181-185.
38. Pulkkinen M.O.: Is there a rationale for the use of Nimesulide in the treatment of Dysmenorrhea? Drugs of Today 2001; 37(suppl. B): 31-38.
39. Rainsford K.D.: Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr. Med. Res. Opin. 2006; 22: 1161-1170.
40. Raju N.C., Eikelboom J.W.: The aspirin controversy in primary prevention. Curr. Opin. Cardiol. 2012; 27: 499-507.
41. Romella G., Costagli V., Vetere M. et al.: Comparision of nimesulide and diclofenac in the prevention and treatment of pain and inflammatory postoperative complications of general surgery. Drugs 1993; 46(suppl. 1): 159-161.
42. Ruoff G., Lema M.: Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J. Pain Symptom. Manage. 2003; 25(suppl. 2): 21-31.
43. Sarzi-Puttini P., Santandrea S., Booccassini L. et al.: The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin. Exp. Rheumatol. 2001; 19(suppl. 22): S17-20.
44. Shah A.A., Thjodleifsson B., Murray F.E. et al.: Selective hibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339-346.
45. Sudano I., Flammer A.J., Roas S. et al.: Nonsteroidal antiinflammatory drugs, acetaminophen and hypertension. Curr. Hypertens. Rep. 2012; 14: 304-309.
46. Sato K., Takahashi H., Toriyama M.: Depigmenting mechanism of NSAIDs on B16F1 melanoma cells. Arch. Dermatol. Res. 2011; 303(3): 171-80.
47. Stępień A.: Bóle głowy. Patofizjologia. Diagnostyka. Leczenie. Medical Tribune Polska, 2010.
48. Venegoni M., Da Cas R., Menniti-Ippolito F. et al.: Następstwa europejskich działań ograniczających przepisywanie nimesulidu: badanie symulacyjne dotyczące zaburzeń czynności wątroby i krwawienia z przewodu pokarmowego przeprowadzone we Włoszech. Ann. Ist. Super Sanita. 2010; 2(46): 153-157.
49. Wielosz E.: Bezpieczeństwo stosowania inhibitorów cyklooksygenazy 2 w racjonalnej terapii bólu ostrego i przewlekłego. Evid. Based Med. 2013; 2(6) (reprint).
50. Wober W.: Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and meta-analysis of controlled studies with nimesulide. Rheumatology 1999; 38(suppl. 1): 33-38.
51. Wordliczek J., Filipczak-Bryniarska I. Wordliczek J. (red.). Akademia Leczenia Bólu. Ogólnopolski Program Edukacyjny 2013.
52. Woroń J.: Wybór niesteroidowego leku przeciwzapalnego w praktyce klinicznej. W: Akademia Leczenia Bólu. Ogólnopolski Program Edukacyjny. Wordliczek J. (red.). 2013.
53. Wordliczek J., Dobrogowski J.: Leczenie bólu. PZWL, 2012.
54. Zenz M., Strumpf M., Strumph-Willweber A.: Leczenie bólu. MedPharm Polska, Wrocław 2011.